RECRUITING

Implementation of Mobile-based Programs for Alcohol Cessation in Treatment of Alcohol-associated Liver Disease

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This protocol describes a randomized controlled trial testing the effectiveness and implementability of the CHESS Health Connections smartphone application among patients with alcohol-associated liver disease (ALD) at two medical centers in Michigan and Wisconsin, in two types of clinics: general hepatology and multidisciplinary that offers care for advanced ALD alongside co-located, integrated mental health and substance abuse treatment. The long-term goal of this and future work is to prevent disease progression and promote healthy behaviors by improving the rate of abstinence among patients with ALD earlier in the course of their disease. 298 participants will be enrolled and can expect to be on study for up to 6 months.

Official Title

Implementation of Mobile-based Programs for Alcohol Cessation in Treatment of Alcohol-associated Liver Disease (IMPACT-ALD): Aim 1

Quick Facts

Study Start:2024-06-24
Study Completion:2027-09
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06305624

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Diagnosis of ALD (any stage)
  2. * Alcoholic liver disease (ALD) encompasses a spectrum of hepatic injuries caused by long-term alcohol abuse. For this study, participants will have a diagnosis of ALD and/or steatosis (fatty liver disease), or alcoholic hepatitis, or liver cirrhosis. Only one of the above diagnoses is needed to be eligible for this study.
  3. * Alcohol use within the last 6 months
  4. * Receiving care at UW or UM
  5. * Either the general hepatology clinic or the multidisciplinary ALD clinic
  6. * Able to read and write proficiently in English
  7. * Willing and able to use a smartphone app
  1. * Actively listed for liver transplant or history of liver transplant before being enrolled in the study. Participants added to a liver transplant list after being enrolled in the study will be allowed to continue their participation
  2. * In hospice care
  3. * Has severe cognitive impairment (as described in electronic health record including dementia, delirium, and/or unable to maintain cognitive alertness during screening--as determined by study staff.)

Contacts and Locations

Study Contact

Mary M Checovich, MS CCRC
CONTACT
608-263-2653
mary.checovich@fammed.wisc.edu

Principal Investigator

Andrew Quanbeck, PhD
PRINCIPAL_INVESTIGATOR
University of Wisconsin, Madison

Study Locations (Sites)

Henry Ford + Michigan State University Health Center
Lansing, Michigan, 48824
United States
UW General Hepatology Clinic
Madison, Wisconsin, 53705
United States
UW Multidisciplinary ALD Clinic
Madison, Wisconsin, 53705
United States

Collaborators and Investigators

Sponsor: University of Wisconsin, Madison

  • Andrew Quanbeck, PhD, PRINCIPAL_INVESTIGATOR, University of Wisconsin, Madison

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-06-24
Study Completion Date2027-09

Study Record Updates

Study Start Date2024-06-24
Study Completion Date2027-09

Terms related to this study

Additional Relevant MeSH Terms

  • Alcohol Use Disorder
  • Alcohol-related Liver Disease